Gram-Scale Synthesis of Site-Specific Antibody-Drug Conjugates Using AJICAP Second-Generation Technology
Preprint
- 5 April 2023
- preprint
- Published by American Chemical Society (ACS) in ChemRxiv
Abstract
Chemical site-specific conjugation technology utilizing immunoglobulin-G (IgG) Fc-affinity reagents is a versatile and promising tool for producing next-generation antibody-drug conjugates (ADCs). Our research group recently reported a novel Fc-affinity peptide-mediated conjugation method, termed AJICAP second-generation. This technology, based on thioester chemistry, produces site-specific ADCs without aggregation. Herein, we report further investigations into the AJICAP second-generation technology. By varying the parameters of the peptide conjugation step, it was found that this reaction is feasible under a wide range of reaction conditions. All synthetic intermediates of the AJICAP-ADCs were sufficiently stable, indicating that each synthetic step is a possible holding point in ADC manufacturing. The Lys248- and Lys288-conjugated ADCs were prepared on a gram-scale using two different Fc-affinity peptide reagents, employing a scale-down manufacturing approach involving tangential flow filtration (TFF). The total product yield was > 80%, and ultimately, 13.2 g of trastuzumab-Lys248-MMAE and 1.26 g of trastuzumab-Lys288-MMAE were obtained with high drug to antibody ratios (DARs). The results strongly indicate that the AJICAP second-generation method is a robust and practical approach for the manufacture of ADCs.Keywords
All Related Versions
This publication has 18 references indexed in Scilit:
- AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate ProductionBioconjugate Chemistry, 2023
- Site-Selective Antibody–Drug Conjugation by a Proximity-Driven S to N Acyl Transfer Reaction on a Therapeutic AntibodyJournal of Medicinal Chemistry, 2022
- Lipoate-acid ligase a modification of native antibody: Synthesis and conjugation site analysisBioorganic & Medicinal Chemistry Letters, 2021
- Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody–Drug ConjugatesMolecular Pharmaceutics, 2021
- Chromatographic analysis of site-specific antibody-drug conjugates produced by AJICAP first-generation technology using a recombinant FcγIIIa receptor-ligand affinity columnJournal of Chromatography B, 2021
- Insight into Temperature Dependency and Design of Experiments towards Process Development for Cysteine‐Based Antibody‐Drug ConjugatesChemistrySelect, 2020
- Antibody-drug conjugates- stability and formulationEuropean Journal of Pharmaceutics and Biopharmaceutics, 2019
- Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocolJournal of Pharmaceutical and Biomedical Analysis, 2018
- Solubility Challenges in High Concentration Monoclonal Antibody Formulations: Relationship with Amino Acid Sequence and Intermolecular InteractionsMolecular Pharmaceutics, 2015
- Sequential learning in non-human primatesTrends in Cognitive Sciences, 2001